Prognose

Das durchschnittliche Kursziel der Analysten beträgt +4,74€(+115,45%). Der Median liegt bei +4,74€(+115,45%).

Kaufen	6
Halten	0
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	3 / 18
Levermann-Strategie	-6 / 13

News

Savara Announces Participation in the Leerink Global Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company's corporate website at https://savaraphar.» Mehr auf businesswire.com
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On February 12, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 97,500 shares of the Company's common stock and restr.» Mehr auf businesswire.com
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, “Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis Treated with Molgramostim Inhalation Solution" was published online in the journal ERJ Open Research. The outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, r.» Mehr auf businesswire.com

Unternehmenszahlen

Im letzten Quartal hatte Savara Inc einen Umsatz von 0,00€ und ein Nettoeinkommen von −21,77 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	100,00%
Nettoeinkommen	−21,77 Mio	38,87%
EBITDA	−23,64 Mio	38,92%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+377,29 Mio€
Anzahl Aktien	171,62 Mio
52 Wochen-Hoch/Tief	+5,40€ - +2,19€
Dividenden	Nein
Beta	0,6
KGV (PE Ratio)	−5,93
KGWV (PEG Ratio)	+2,49
KBV (PB Ratio)	+2,47
KUV (PS Ratio)	0,00

Unternehmensprofil

Savara Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf seltene Atemwegserkrankungen konzentriert. Sein führender Produktkandidat ist Molgramostim, ein inhalativer Granulozyten-Makrophagen-Kolonie-stimulierender Faktor, der sich in der Phase III der Entwicklung zur Behandlung der autoimmunen pulmonalen alveolären Proteinose befindet. Der Hauptsitz des Unternehmens befindet sich in Austin, Texas.